Radius Recycling, Inc. - Class A Common Stock (RDUS)

BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.

BOSTON, MA / ACCESSWIRE / December 9, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Theramex the exclusive commercialization rights to ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, for Mexico, Canada, Israel, South Africa, and Russia. Theramex will also have the opportunity to commercialize ELADYNOS® in other agreed upon unpartnered regions. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.

TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data

Radius Recycling, Inc. (NASDAQRDUS), a global leader in metals recycling, has been recognized as one of the 2024 World’s Most Ethical Companies by Ethisphere, a world leader in defining and advancing the standards of ethical business practices. Radius is among this year’s 136 honorees spanning 20 countries and 44 industries.

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQRDUS) today reported results for the first quarter of fiscal 2024 ended November 30, 2023.

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQRDUS) announced that the Company will report financial results for its first quarter fiscal 2024 ended November 30, 2023 on Thursday, January 4, 2024. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed on Radius Recycling’s website at www.radiusrecycling.com/company/investors. The call will be hosted by Tamara Lundgren, Chairman and Chief Executive Officer, and Stefano Gaggini, Senior Vice President and Chief Financial Officer.

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQRDUS), a global leader in metals recycling, today announced the release of the Company’s Fiscal 2023 Sustainability Report, Where Change Begins.

Today, TIME named Schnitzer Steel Industries, Inc. dba Radius Recycling’s (NASDAQRDUS) Chairman and Chief Executive Officer, Tamara Lundgren, to the inaugural TIME100 Climate List, recognizing the 100 most innovative leaders who are working to advocate for and expedite climate action.

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQRDUS) today reported results for the fourth quarter of fiscal 2023 ended August 31, 2023.

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQRDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2023 ended August 31, 2023 on Wednesday, October 25, 2023. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed under the Events Calendar on Radius Recycling’s website at www.radiusrecycling.com/company/investors. The call will be hosted by Tamara Lundgren, Chairman and Chief Executive Officer, and Stefano Gaggini, Senior Vice President and Chief Financial Officer.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Radius Health, Inc. (NasdaqGM: RDUS) to Gurnet Point Capital and Patient Square Capital. Under the terms of the proposed transaction, shareholders of Radius will receive only $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share for each share of Radius that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement:

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQRDUS) for potential breaches of fiduciary duty on the part of its directors and management.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQRDUS) for potential breaches of fiduciary duty on the part of its directors and management.

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today issued the following comment in response to the proposed acquisition of Radius by Gurnet Point Capital and Patient Square Capital in a transaction valued at up to approximately $890 million:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Radius Health, Inc. (NasdaqGM: RDUS) to Gurnet Point Capital and Patient Square Capital. Under the terms of the proposed transaction, shareholders of Radius will receive only $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share for each share of Radius that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Radius Health, Inc. (NASDAQRDUS) to Gurnet Point Capital and Patient Square Capital is fair to Radius Health shareholders. Under the terms of the merger agreement, Gurnet Point and Patient Square will acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a Contingent Value Right of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during any consecutive 12-month period prior to December 31, 2025.

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, announced today that it has issued a detailed presentation on the need for board-level change at the Company in connection with the upcoming 2022 Annual Meeting of Stockholders to be held on July 8, 2022 (the "Annual Meeting"). Velan-Repertoire also mailed a letter to fellow Radius stockholders detailing the Board of Directors’ (the “Board”) troubling track record of value destruction and calling on Radius stockholders to send a strong message to the Board at the upcoming Annual Meeting that the status quo can no longer continue.

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), today sent a letter to Radius’ Board of Directors (the “Board”).

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today responded to recent statements made by the Radius Board of Directors (the “Board”).

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQRDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, announced today that it has filed definitive proxy materials in connection with its nomination of Eric Ende, Cynthia Flowers and Ann MacDougall to the Radius Board of Directors (the “Board”) at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”). Velan-Repertoire also announced that it has mailed a letter to fellow Radius stockholders detailing the Board’s troubling track record of value destruction and calling on Radius stockholders to send a strong message to the Board at the upcoming Annual Meeting to be held on July 8, 2022 that meaningful change is immediately required. Velan-Repertoire also launched a website, fixradius.com, which contains important stockholder materials in connection with its campaign, including its definitive proxy statement for the Annual Meeting and instructions for contacting its proxy solicitor, Okapi Partners.